01.

OFFERING STRUCTURE
Issuer Optimax Holdings Berhad (“Optimax” or the “Company”)
Principal Adviser,
Sole Placement
Agent, Sole
Underwriter,
Sponsor
Offering Structure A public issue of 70,000,000 new shares (“IPO Shares”) for application
➢ 13,500,000 IPO Shares by the Malaysian public
➢ 4,000,000 IPO Shares by eligible employees and directors of Optimax and its subsidiaries (“Optimax Group”)
➢ 27,000,000 IPO Shares to Bumiputera investors approved by the Ministry of International Trade and Industry of Malaysia (“MITI”)
➢ 25,500,000 IPO Shares to Malaysian institutional and selected investors (other than Bumiputera investors approved by the MITI)

Listing Sought ACE Market of Bursa Malaysia Securities Bhd (“ACE Market”)
Issue Price RM0.30 per IPO Share
Market RM81 million upon listing
Capitalisation
Capital Structure No. of shares Share capital (RM’000) Timeline Event Date
Existing share capital 200,000,000 19,500
Opening date of application for our 10.00 a.m., 15 July 2020
Public issue 70,000,000 19,571 IPO Shares
Enlarged share 270,000,000 39,071
capital Closing date of application for our 5.00 p.m., 4 August 2020
Use of Proceeds Proposed use RM’000 % Est. timeframe IPO Shares
Balloting of applications 6 August 2020
Capital expenditure 10,354 49.3 Within 12 months
Repay borrowings 3,526 16.8 Within 3 months
Working capital 3,520 16.8 Within 12 months Allotment of IPO shares to successful 14 August 2020
applicants
Defray fees and IPO
3,600 17.1 Within 1 months
expenses
Listing 18 August 2020
TOTAL 21,000 100.0 -

02. SHAREHOLDING & CORPORATE STRUCTURE 03. BUSINESS OVERVIEW

►Provider of eye specialist services with a chain of 13 eye specialist
Founding centres in Malaysia.
Datin Lim 0.0001% Doctors
• Dr. Stephen ►1 specialist hospital, 11 ambulatory care centres (“ACC”) and 1
Sho Hoo specialist clinic in Malaysia.
Chung
5.69%
spouse ►We offer a range of services with in-house expertise in medical
99.9999% ophthalmology at specialist centres, as below:
Sena • Dr Chuah
Dato Tan Healthcare Kay Leong Others &
Boon Hock Services 3.73% Public i. Treatment of eye diseases and disorders iv. Oculoplastic surgery
Sdn Bhd ii. Refractive surgery v. Eye examination
iii. Consultation and dispensary services vi. Others
31.80% 29.21%

*61.77% Optimax 9.42% #28.81% 04. KEY INVESTMENT HIGHLIGHTS

100%
A TRACK RECORD OF 25 YEARS TO SERVE
OESC
AS REFERENCE TO NEW CUSTOMERS
• Developed an established brand name under
“Optimax”.
OESC (Ipoh) OESC (Seri Petaling) • From the financial years 2016 to 2019, we have
100% 70%
performed a total of 25,655 surgeries.
100% OESC (Seremban) OESC (Bandar Sunway) 70%
100% OESC (Shah Alam) OESC (Southern) 70% AN ESTABLISHED NETWORK OF PRIVATE
100%
100% OESC (Kuching) Inspirasi 100% EYE SPECIALIST CENTRES IN MALAYSIA
Alamjaya OESC (Muar)
Notes: (Johor Bahru) • We operate 13 eye specialist centres in Malaysia.
• Optimax Eye Specialist Centre Sdn Bhd 90% 90% • An extended network of eye specialist centres is
(“OESC”) OESC OESC important to provide market reach and consumer
• OESC fully owns one (1) specialist hospital (Kluang) (Segamat) convenience.
(George Town) and two (2) ACCs (TTDI and
Klang) OESC (Kajang) (Dormant) 79%
• *Collectively, Dato Tan Boon Hock holds
OUR STAKEHOLDERS ARE RESIDENT EYE
Optixanthin Sdn Bhd 90%
61.77% in Optimax through the interests of SURGEONS IN THEIR RESPECTIVE EYE
his children, Sandy Tan and Michelle Tan, and
his interest in Sena Healthcare Services Sdn
SPECIALIST CENTRES
Bhd. • All of our eye surgeons are medical practitioners licensed
• #Excludes Sandy Tan and Michelle Tan’s Pink by the Malaysian Medical Council, and are registered
form shares allocation. ophthalmologists under the National Specialist Register.
 05. FUTURE PLANS
EXPANSION IN THE CENTRAL REGION

❖ Penang
❑ Ulu Tiram
❑ Muar
❑ Ipoh
❑ Kluang
❑ Bandar ❑ Segamat
Sunway
❑ Klang
Legend:
❑ Shah Alam ❖ specialist
hospital
➢ Seremban ❑ ACC
❑ Taman Tun Dr
❑ Kuching ➢ specialist clinic
Ismail
❑ Seri Petaling

► As part of our efforts to convert our specialist clinic in Seremban into an ACC, we had begun renovation works and upon the completion of the renovation,
the ACC would be able to provide additional eye provision specialist services including refractive and cataract surgery (estimated 4th quarter of 2020).

PURCHASE NEW OPHTHALMOLOGICAL EQUIPMENT AND TOOLS

Phaco PentacamAngio optical

Fundus
Machine coherence
Camera
tomography
► We have allocated RM5.00 million from our IPO proceeds to purchase new operation equipment and tools for our existing specialist centres for the
provision of our eye specialist services.

06. FINANCIAL OVERVIEW

Revenue (RM'000)
2016 – 2019 Revenue CAGR: +28%
Profit Before Tax ("PBT") (RM'000)
68,000

2016 – 2019 PAT CAGR: +41% 62,619 50.00%

Profit After Tax ("PAT") (RM'000) 45.00%

58,000

Profit After Tax and Non-Controlling Interests 49,234 40.00%

48,000
(RM'000)
PBT Margin (%) 35.00%

38,000
36,015 26.61% 30.00%

29,962 25.00%

28,000 20.08%
15.55% 15.84%
20.00%

18,000
12,572 15.00%

9,583 7,380 7,390 7,801 8,739 7,831

4,660 3,135 3,240 4,970 4,445
10.00%

8,000

5.00%

-2,000 0.00%

FYE 2016 FYE 2017 FYE 2018 FYE 2019

Treatment of eye diseases and disorders

26,724
Refractive surgery Segmental revenue contribution (RM’000)
43% 22,985
Consultation and dispensary services
20,692
Oculoplastic surgery 18,478 37%
16,386 42%
Related Services
38%
13,731
11,78846%
46% 9,450
8,694 33%
1,472 6,904
29%
1,342 15% 978
4,136 1,466
3,307 2,888 14% 2,482
2,233 1,694
11%
11%
4% 10% 4% 6% 3% 3% 1% 4%
FYE 2016 FYE 2017 FYE 2018 FYE 2019